Abstract:
Disclosed is a whitening composition for external skin application. Containing one or more of Oldenlandia diffusa Willd extract, Rheum undulatum extract and Broussonetia kazinoki extract as an effective ingredient, the whitening composition for external skin application exhibits superior melanogenesis inhibition and skin whitening effect. Accordingly, it may be used in various skin whitening cosmetics.
Abstract:
The present invention relates to a biomarker for diagnosing hyperpigmentation of skin, which comprises a gene selected from the group consisting of genes listed in Table 1, or a protein selected from the group consisting of proteins listed in Table 1.
Abstract:
Disclosed are a kit for diagnosing skin aging using one or more polynucleotides or their complementary polynucleotides that hybridize with a gene sequence, a pair of primers for the gene sequence; or one or more monoclonal antibodies binding to the polypeptide encoded by the gene, which are used to identify the genes of which the expression pattern is changed in a skin keratin-forming cell by female hormone and used to diagnose degree of skin aging caused by female hormonal deficiency by using the information, and a method using the same.
Abstract:
PURPOSE: A method for screening an agent for preventing aberrant keratinocyte differentiation is provided to use a gene as a gene target for developing a therapeutic agent for treating dermatitis and to evaluate the agent. CONSTITUTION: A method for screening an agent for preventing aberrant keratinocyte differentiation comprises: a step of transfection of plasmids to cells; a step of treating the cell to a test compound; and a step of identifying whether the test compound stimulates the reporter gene. The plasmids includes: a plasmid containing Nrf-2 gene and universal promoter; a plasmid contains DNA which binds with a transcription factor and a reporter gene; and a plasmid containing Nkx-2.5, AP-1, MEIS1A/HOXA9, MEIS1B/HOXA9, CREB, ISRE-BP, Hand1/E47, Pax-6, c-Myb, v-Maf, Elk-1, E47, CRE-BP1, IRF-1, IRF-2, c-Rel, c-Ets-1(p54), USF, VBP, Hox-1.3, Brn-2, COMP1-factor, CDP_CR1, CP2 or NF-kB(p50) gene and a universal promoter. The agent is a therapeutic agent for treating psoriasis. [Reference numerals] (AA) Gene pattern in which expression is reduced during differentiation; (BB) Relative expression level(times); (CC) Time(days)
Abstract:
The present invention provides hydroxamic acid derivatives represented by the following formula (I), having anti-aging efficacy and a method for preparation thereof: wherein, R1 is or, herein, R5 and R6 each independently represents a hydrogen atom, a C1-C10 alkyl group or a C3-C6 cyclic alkyl group; R2 is CONH, NHCO, CONR7 or NR7CO, herein, R7 represents a C1-C10 alkyl group; R3 is (CH)n-, herein, n=0 or 1; and R4 is a hydrogen atom or a C1-C10 alkyl group. Further, the present invention provides skin-care external compositions for preventing skin aging, containing said hydroxamic acid derivatives represented by the formula (I) as an active ingredient.